Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

NGM Biopharmaceuticals logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

Advanced Chart

Key Stats

Today's Range
$1.54
$1.54
50-Day Range
$1.52
$1.63
52-Week Range
$0.60
$4.69
Volume
N/A
Average Volume
1.47 million shs
Market Capitalization
$128.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NGM Stock News Headlines

Small Washington, DC Group Could Crash US Stocks
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."tc pixel
See More Headlines

NGM Stock Analysis - Frequently Asked Questions

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.03. The business had revenue of $18.58 million for the quarter, compared to analysts' expectations of $18.90 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%.

NGM Biopharmaceuticals (NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL).

Company Calendar

Last Earnings
11/04/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
CIK
1426332
Fax
N/A
Employees
138
Year Founded
1998

Profitability

EPS (Trailing Twelve Months)
($1.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$142.38 million
Net Margins
-3,223.34%
Pretax Margin
-3,223.34%
Return on Equity
-77.85%
Return on Assets
-67.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.79
Quick Ratio
7.79

Sales & Book Value

Annual Sales
$4.42 million
Price / Sales
29.10
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.80 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
83,462,000
Free Float
53,499,000
Market Cap
$128.53 million
Optionable
Optionable
Beta
1.27

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:NGM) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners